KRAS Seven Mutations Detection Kitt
Request Price Quote
The AmoyDx KRAS Seven Mutations Detection Kit is a sensitive and selective assay for the detection of the most common somatic mutations in the KRAS gene.
The KRAS gene mutation status of colorectal cancer patients is relevant to drug resistance of targeted medicines such as tyrosine kinase inhibitors. Patients with wild-type KRAS gene are much more likely to benefit from the Erbitux (Cetuximab) or Vectibix (Panitumumab), compared to patients with a mutant KRAS gene. The European Drug Administration Organization and US FDA recommended the employment of KRAS gene mutation test prior to the usage of targeted medicine Erbituxand and Vectibix in the treatment of colorectal cancer.
Intended Use: For research purpose use only. To aid doctors to identify colorectal cancer patients who are more likely to benefit from anti-EGFR therapies such as Cetuximab and Panitumumab.
Technological Principles: The KRAS seven mutations detection kit employs a real-time PCR format combined with patented technology - “mutation specific amplification technology” - to detect mutations in DNA samples. The method is much more specific and sensitive than alternative technologies such as DNA sequencing.
The KRAS seven mutations detection kit enables detection of the following mutations in codons 12 and 13 against a background of wild-type genomic DNA.
|Product Name||Size (test/Kit)||Storage||Cat. No.|
|KRAS Seven Mutations Detection Kit||12t||-20 ° C||ADx-KR01|